Relmada Therapeutics Stock (NASDAQ:RLMD)
Previous Close
$3.42
52W Range
$1.88 - $7.22
50D Avg
$3.26
200D Avg
$3.85
Market Cap
$100.18M
Avg Vol (3M)
$191.13K
Beta
0.51
Div Yield
-
RLMD Company Profile
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| ENOB | Renovaro Biosciences Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| NUVB | Nuvation Bio Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| FUSN | Fusion Pharmaceuticals Inc. |
| DYN | Dyne Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| EWTX | Edgewise Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| GRPH | LENZ Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| THRD | Third Harmonic Bio, Inc. |
| NLTX | Neurogene Inc. |
| CYTK | Cytokinetics, Incorporated |
| KRTX | Karuna Therapeutics, Inc. |
| BCYC | Bicycle Therapeutics plc |
| PRDS | Pardes Biosciences, Inc. |
| STTK | Shattuck Labs, Inc. |
| RAPT | RAPT Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |